
Flow Neuroscience
Develops a new kind of depression treatment which combines an easy-to-use brain stimulation headset with a personalized mobile app.
- B2C
- marketplace & ecommerce
- saas
- manufacturing
- commission
- subscription
- health
- wellness beauty
- health platform
- medical devices
- biotechnology
- connected device
- deep tech
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor investor investor | €0.0 | round |
investor | €0.0 | round | |
investor investor investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor investor investor investor investor investor investor | €0.0 | round | |
investor | €0.0 | round | |
* | N/A | Support Program | |
Total Funding | 000k |
EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% growth | - | - | 279 % | 34 % | 166 % | 162 % | 101 % |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% EBITDA margin | - | (594 %) | (171 %) | (452 %) | - | - | - |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
% profit margin | - | (667 %) | (205 %) | (486 %) | (318 %) | (162 %) | (71 %) |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Flow Neuroscience is a medical device company that has developed an at-home treatment for depression. The company's primary offering is a headset that uses transcranial direct current stimulation (tDCS) to target the dorsolateral prefrontal cortex, the area of the brain responsible for regulating mood. This headset is paired with a mobile application that provides a virtual therapy program. The treatment is designed for individuals diagnosed with major depressive disorder (MDD) and is available for purchase or rent directly from the company's website.
The business model is direct-to-consumer, with a focus on providing a medication-free alternative for depression treatment. The company has received regulatory approval in Europe (CE mark) and the UK, and is seeking FDA approval in the United States. The treatment program is based on clinical evidence and research, with several studies supporting its efficacy in reducing depressive symptoms.
Keywords: depression treatment, tDCS, medical device, mental health, neurostimulation, at-home treatment, virtual therapy, direct-to-consumer, CE marked, medication-free
Tech stack
Investments by Flow Neuroscience
Edit